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Cancers like glioblastoma remain unmanageable for most 
patients and even with the current optimal treatment offered, 
survival rates are far too low. Fortunately, several preclinical 
and clinical studies indicate that oncolytic viruses have the 
potential to effectively eradicate cancers. Data from one such 
clinical trial, DNX-240, a recently completed first-in-human 
Phase I clinical trial using Delta-24-RGD to treat recurrent 
glioblastoma (NCT00805376) demonstrated that the oncolytic 
virus successfully excites an antitumor immune response.The 
oncolytic adenovirus Delta-24-RGD includes a deletion in the 
E1A region that confers tumor-selective infectivity and an RGD 
peptide motif insertion that improves infective power. 
The genome of Delta-24-RGDOX-DH was amplified by PCR and 
sequenced to ensure the viral construct incorporated the appropriate genetic 
modifications. Next, the expression of murine OX40L in the membrane of 
infected cells was assessed using western blot and flow cytometry and the 
expression of other viral proteins by infected cells was analyzed by western 
blotting. The presence of immune cell populations in tumor-bearing mice was 
measured between treatment groups with flow cytometry. Afterwards, the 
oncolytic effects of oncolytic viruses were tested by infecting A549 human lung 
carcinoma cells and measuring cell counts over time. Then, studies of mice were 
conducted to compare the therapeutic effect of viruses on 4T1-derived breast 
tumors compared to a mock infection. 
● The Delta-24-RGDOX-DH genome had all the desired genomic 
alterations that give it the ability to selectively infiltrate and lyse 
cancer cells, demonstrating reliability in production and utility. 
● Experiments showed that Delta-24-RGDOX-DH produced a 
substantial infection in vitro and in vivo with effective cancer cell 
lysis and increased activation of the immune system in 
tumor-bearing mice. 
● Experiments also showed the modified virus produces the 
necessary costimulatory ligand to maximize infection and 
reinvigorate immune lymphocytes. 
● Delta-24-RGDOX-DH shows promising signs of efficacy as an 
anti-cancer therapy, so our data should propel the development of 
clinical trials with Delta-24-RGDOX-DH for patients with high-grade 
glioma, or other aggressive types of cancer. 
We hypothesize that the anti-tumor effect might be amplified 
by the expression of positive immune checkpoints. 
To test this, we incorporated a costimulatory ligand (OX40L) 
after the fiber region to maximize T-cell activity, which generated 
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Figure 1. Schematic Illustration of Intended Modifications to the 
Delta-24-RGDOX-DH viral genome
Delta-24-RGDOX-DH’s modifications to the adenovirus genome are: 1. a 24bp 
deletion in E1A region to allow tumor-selective infectivity, 2. an RGD-4C peptide 
motif insertion in the Fiber region to boost infectivity of cancer cells. 3. the 
addition of the sequence coding for the costimulatory ligand OX40 after the Fiber 
region to prompt the immune system to target infected cancer cells
Figures 3 (Left), 4 (Right). Delta-24-RGDOX-DH Sequences of Note
Amplifying (Figure 2) and sequencing (Figure 3) Delta-24-RGDOX-DH DNA 
indicates the viral construct integrates every  necessary edit to form a functional, 
immune-stimulating oncolytic virus. 
Figure 6. Flow Cytometry of Infected A549 Cells Showing Appropriate 
Expression of  OX40L on Cell Surface
Virally-infected A549 lung carcinoma cells (5MOI) collected at 48 hours 
present OX40L only once infected with Delta-24-RGDOX-DH
Figure 5. Western Blot Testing Infection-Competency and OX40L 
Expression on A549 Cell Surface
Only cells infected with an oncolytic virus expressed the proteins Hexon 
and Fiber which indicate infection-capability. Additionally, the cells infected 
with the oncolytic viruses that incorporate a costimulatory ligand 
sequence expressed OX40L on their cell surface. 
Figure 8. Cell Viability Assay 
There was an  85% reduction in cell viability by Day 4 in cells infected with 
Delta-24-RGDOX-DH compared to cells infected with PBS. 
(2-way ANOVA, p=0.0015)
Figure 1. Maximum Change in Tumor Size Among 
Recurrent Malignant Glioma Patients Treated with 
1 Dose of Delta-24-RGD (Lang e/ al., JCO, 2018)
For the majority of patients, the size of their tumors 
decreased markedly. Figure 2. Patient Survival in 
Months According to Treatment 
Dose 
5 patients survived past 3 years
Figure 9 (right). Kaplan-Meier Graph Depicting Survival in 
Mice with Breast Cancer Treated with Virus vs. Mock 
Virus 
Shows that mice treated with Delta-24-RGDOX survived 
significantly longer than the mock treatment mice (p=0.0070).
Figure 7. With the immune cell population analysis in the tumor, there is a trend 
toward an activation of anti-tumor immunity with an increase in CD8+ T cells, Natural 
Killer cells, and Myeloid-Derived Suppressor Cells, and a decrease in CD4+ T cells 
and Regulatory T cells. 
